These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33281543)

  • 21. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
    Blennow K; Biscetti L; Eusebi P; Parnetti L
    Mov Disord; 2016 Jun; 31(6):836-47. PubMed ID: 27145480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cerebrospinal fluid markers in early diagnosis of Alzheimer dementia].
    Wiltfang J
    Ther Umsch; 2015 Apr; 72(4):271-8. PubMed ID: 25791051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neural underpinnings of motor learning in people with neurodegenerative diseases: A scoping review.
    Aslan DH; Hernandez ME; Frechette ML; Gephart AT; Soloveychik IM; Sosnoff JJ
    Neurosci Biobehav Rev; 2021 Dec; 131():882-898. PubMed ID: 34624367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular blood flow as a clinical observation: Value, limitations and data analysis.
    Harris A; Guidoboni G; Siesky B; Mathew S; Verticchio Vercellin AC; Rowe L; Arciero J
    Prog Retin Eye Res; 2020 Jan; ():100841. PubMed ID: 31987983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.
    Htike TT; Mishra S; Kumar S; Padmanabhan P; Gulyás B
    Mol Neurobiol; 2019 Mar; 56(3):2256-2277. PubMed ID: 30008073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glaucoma as a dangerous interplay between ocular fluid and cerebrospinal fluid.
    Wostyn P
    Med Hypotheses; 2019 Jun; 127():97-99. PubMed ID: 31088658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease.
    Omar SH; Preddy J
    J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32708853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.
    Kim D; Kim YS; Shin DW; Park CS; Kang JH
    J Clin Neurol; 2016 Oct; 12(4):381-392. PubMed ID: 27819412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics.
    Zimmermann R; Beck G; Knispel S; Maler JM; Weih M; Wiltfang J; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2010; 19(4):1199-203. PubMed ID: 20308786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a relation between extremely low frequency magnetic field exposure, inflammation and neurodegenerative diseases? A review of in vivo and in vitro experimental evidence.
    Mattsson MO; Simkó M
    Toxicology; 2012 Nov; 301(1-3):1-12. PubMed ID: 22750629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neurological disorders and glaucoma - an overview].
    Göbel K; Erb C
    Klin Monbl Augenheilkd; 2014 Feb; 231(2):130-5. PubMed ID: 24532400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain atrophy in peritoneal dialysis and CKD stages 3-5: a cross-sectional and longitudinal study.
    Tsuruya K; Yoshida H; Kuroki Y; Nagata M; Mizumasa T; Mitsuiki K; Yoshiura T; Hirakawa M; Kanai H; Hori K; Hirakata H; Kitazono T
    Am J Kidney Dis; 2015 Feb; 65(2):312-21. PubMed ID: 25218680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in Management of Psychosis in Neurodegenerative Diseases.
    Rothenberg KG; Rajaram R
    Curr Treat Options Neurol; 2019 Jan; 21(1):3. PubMed ID: 30673880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of hospitalization with neurodegenerative disease after moderate-to-severe traumatic brain injury in the working-age population: A retrospective cohort study using the Finnish national health registries.
    Raj R; Kaprio J; Korja M; Mikkonen ED; Jousilahti P; Siironen J
    PLoS Med; 2017 Jul; 14(7):e1002316. PubMed ID: 28678790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shaping the Nrf2-ARE-related pathways in Alzheimer's and Parkinson's diseases.
    Fão L; Mota SI; Rego AC
    Ageing Res Rev; 2019 Sep; 54():100942. PubMed ID: 31415806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SVM Based Descriptor Selection and Classification of Neurodegenerative Disease Drugs for Pharmacological Modeling.
    Shahid M; Shahzad Cheema M; Klenner A; Younesi E; Hofmann-Apitius M
    Mol Inform; 2013 Mar; 32(3):241-9. PubMed ID: 27481519
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.